SHANGHAI, Sept. 20, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been orally presented at the European Society of Medical Oncology Congress 2021 (ESMO 2021). The presenter was Dr. Changsong Qi from Beijing Cancer Hospital.